ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biomarkers"

  • Abstract Number: 1239 • ACR Convergence 2020

    Peripheral Protein Biomarker Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis

    Peter Taylor1, Amer Mirza2, Bryan Downie2, Jinfeng Liu2, Rachael Hawtin2 and Emon Elboudwarej2, 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster City

    Background/Purpose: Filgotinib (FIL), an oral selective JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA),…
  • Abstract Number: 1567 • ACR Convergence 2020

    Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)

    Despina Michailidou1, Ali R Khaki2, Guangyu Wang3, Leonidas Diamantopoulos2 and Petros Grivas2, 1Division of Rheumatology, University of Washington, Seattle, Washington, Seattle, WA, 2Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, Seattle, WA, 3Department of Biostatistics, University of Washington, Seattle, Washington, Seattle, WA

    Background/Purpose: Patients with cancer treated with CPI can develop irAEs. Since immune changes may impact blood counts and ratios, we hypothesized that those would be…
  • Abstract Number: 1809 • ACR Convergence 2020

    Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters

    Fabien Vincent1, Jannina Ong1, Alberta Hoi2, Sarah Boyd1, Hieu Nim1 and Eric Morand3, 1Monash University, Clayton, Victoria, Australia, 2Monash University, Melbourne, Victoria, Australia, 3Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: SLE is a heterogeneous disease, where a better understanding of molecular differences between patients is needed in order to direct therapy. Existing approaches generally…
  • Abstract Number: 2039 • ACR Convergence 2020

    Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma

    Britany Adler1, Ami Shah2, Francesco Boin3, Paul Wolters3, Livia Casciola-Rosen4 and Antony Rosen1, 1Johns Hopkins University, baltimore, MD, 2Johns Hopkins University School of Medicine, Ellicott City, MD, 3University of California, San Francisco, San Francisco, CA, 4Johns Hopkins University, Johns Hopkins University, MD

    Background/Purpose: Scleroderma is a systemic fibrosing disease of unknown etiology that often manifests with interstitial lung disease (ILD). Prior studies have found an association between…
  • Abstract Number: 0171 • ACR Convergence 2020

    Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI

    Jacob Mitchell1, Sara Alehashemi2, Bernadette Marrero3, Yan Huang4, Sofia Torreggiani1, Lena Bichell1, Gina Montealegre Sanchez5, Raphaela Goldbach-Mansky6 and Adriana de Jesus7, 1Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, 3Computational Systems Biology Section/NIAID/NIH, Bethesda, MD, 4NIH, Bethesda, 5NIAID/NIH, Rockville, MD, 6Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD, 7Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD

    Background/Purpose: The disease progression of patients (pts.) with type-I interferon (IFN)-mediated diseases undergoing treatment with JAK1 and JAK2 inhibitors is monitored in part by measuring…
  • Abstract Number: 0562 • ACR Convergence 2020

    The Relationship Between Heart Disease Risk Profile and Osteoarthritis, Overall and by Multi-/Single-Joint Involvement

    Anthony Perruccio1, Shatabdy Zahid2, Calvin Yip3, J Denise Power2, Mayilee Canizares2, George Heckman4 and Elizabeth Badley1, 1Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada, 2Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: Osteoarthritis (OA) and heart disease (HD) are among the most common chronic conditions. Several studies have shown that OA increases the risk of HD…
  • Abstract Number: 0776 • ACR Convergence 2020

    The Influence of Adipokine Profile and Periodontal Infection in Early Stages of Rheumatoid Arthritis and First-degree Relatives

    Consuelo Romero-Sanchez1, Juliette De Avila2, Jeimmy Andrea Chaparro-Sanabria3, Philipe Chalem Choueka4, Juan Manuel Bello-Gualtero5, Alejandro Ramos-Casallas2, Lorena Chila-M2 and Wilson Bautista-Molano6, 1Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 2Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 3Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 4Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, 5Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 6University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia

    Background/Purpose: Early RA (eRA) patients have a significant incidence of periodontal inflammation and overweight/obesity. A similar degree of disease activity, functional disability and health-related quality…
  • Abstract Number: 1151 • ACR Convergence 2020

    Implementation and Initial Experience with a Screening Protocol for Inflammatory Hyperferritinemia

    Michael Zhang1, Corinne Schneider2, Vinh Dang2 and Scott Canna3, 1Children's Hospital UPMC, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, 3University of PIttsburgh, Pittsburgh, PA

    Background/Purpose: Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) epitomize a diverse and deadly group of inflammatory hyperferritinemic syndromes. Early biomarkers distinguishing these syndromes, especially…
  • Abstract Number: 1240 • ACR Convergence 2020

    An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis

    Muhammad Shipa1, Su-Ann Yeoh1, Dev Mukerjee2 and Michael Ehrenstein1, 1University College London, LONDON, United Kingdom, 2North Middlesex University hospital NHS Trust, London, United Kingdom

    Background/Purpose: Methotrexate (MTX) can result in an increase in mean corpuscular volume (MCV) of red blood cells. The range of MCV change varies between patients…
  • Abstract Number: 1581 • ACR Convergence 2020

    Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review

    Michael Cunningham1, Carolina Alvarez2, Shruti Saxena Beem3, Todd Schwartz4 and Rumey Ishizawar5, 1UNC Hospitals, Durham, NC, 2University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Miami, FL, 3University of North Carolina at Chapel Hill, Chapel Hill, 4University of North Carolina-Chapel Hill, Chapel Hill, NC, 5University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Immune checkpoint inhibitors (ICIs) target checkpoint proteins PD-1/PD-L1 and CTLA-4 to activate and enhance the cytotoxic effects of T lymphocytes against tumor cells [1-2].…
  • Abstract Number: 1814 • ACR Convergence 2020

    The Association of Urinary Membrane Attack Complex (C5b-9) with Proteinuria and Glomerular Activity in Lupus Nephritis

    Shudan Wang1, Erica Moore2, Brianna Lally3, Beatrice Goilav4, Chaim Putterman3 and Anna Broder5, 1Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, 3Albert Einstein College of Medicine, Bronx, NY, 4The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 5Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

    Background/Purpose: Complement activation is known to play a major role in lupus nephritis (LN). Urinary membrane attack complex (C5b-9) has been shown to correlate with…
  • Abstract Number: 2050 • ACR Convergence 2020

    Autoantibodies Targeting Complement Receptors C3aR and C5aR1 Are Decreased in ANCA-associated Vasculitis and Correlate with a Higher Relapse Rate

    Sebastian Klapa1, Antje Müller2, Andreas Koch3, Anja Kerstein-Staehle4, Wataru Kaehler3, Harald Heidecke5, Susanne Schinke6, Markus Huber-Lang7, Martin Nitschke8, Silke Pitann9, Christian Karsten10, Gabriela Riemekasten11 and Peter Lamprecht2, 1University of Lübeck and Institute of Experimental Medicine, Christian-Albrechts-University of Kiel c/o German Naval Medical Institute, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, 2University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 3Institute of Experimental Immunology, Christian-Albrechts-University Kiel, c/o German Naval Medical Institute, Kronshagen, Germany, 4University of Lübeck, Dept Rheumatology and Clinical Immunology, Luebeck, Germany, 5CellTrend GmbH, Luckenwalde, Germany, 6University of Lübeck, Department of Rheumatology and Clinical Immunology, Luebeck, Germany, 7Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, Ulm, Germany, 8Department of Internal Medicine I, Transplant Center, University of Lübeck, Luebeck, Germany, 9University of Lübeck, Department of Rheumatology and Clinical Immunology,, Luebeck, Germany, 10Institute of Systemic Inflammation Research, University of Lübeck, Luebeck, Germany, 11University of Lübeck, Department of Rheumatology and Clinical Immunology,, Lübeck, Germany

    Background/Purpose: Activation of the alternative and common terminal complement pathways has been shown in ANCA-associated vasculitis (AAV). Circulating titers of the anaphylatoxin C5a are increased…
  • Abstract Number: 0253 • ACR Convergence 2020

    Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis

    Tara Tofighi1, Heather Reich2, Jiandong Su3 and Zahi Touma4, 1Department of Medicine, University of Toronto, Toronto, Canada, 2Division of Nephrology, University of Toronto, Toronto, Canada, 3University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 4University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Clinical trials and observational studies in lupus nephritis (LN) have shown that proteinuria level at 12 months is the best predictor of long-term renal…
  • Abstract Number: 0626 • ACR Convergence 2020

    Early Rise in CRP Is Associated with Progression to Respiratory Failure and Intubation in COVID-19 Patients

    Alisa Mueller1, Tomoyoshi Tamura2, Julia Jezmir3, Erin Penn1, Gregory Keras4, Anthony Massaro5 and Edy Kim5, 1Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 2Brigham and Women's Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, 3Brigham and Women’s Hospital, Department of Medicine, Boston, MA, 4Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 5Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA

    Background/Purpose: During the course of hospitalization, it is often unclear which COVID-19 patients will progress from non-critical to critical illness. Timely identification of these patients…
  • Abstract Number: 0777 • ACR Convergence 2020

    CLEC12A Expression as a Potential Predictor of Disease Activity in Early Rheumatoid Arthritis

    Myriam Vaillancourt1, Philippe Desaulniers1, Guillaume Paré1, Nathalie Pagé1, Asmaa Lachaab1, Anthony Kerever1, Anne-Sophie Julien1, Nathalie Amiable1, Martin Pelletier1, Philippe Tessier1, Louis Bessette2, Paul Fortin3, Laetitia Michou1 and Maria Fernandes1, 1Université Laval, Québec, QC, Canada, 2Laval University, Quebec, Canada, 3CHU de Quebec - Universite Laval, Quebec, Canada

    Background/Purpose: Rheumatoid arthritis (RA) develops as a result of the dysregulation of immune activating and inhibitory pathways. Several lines of evidence indicate that inhibitory receptors…
  • « Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 96
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology